A Nitric Oxide-Releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis through Antimicrobial and Anti-Inflammatory Activity

J Invest Dermatol. 2020 Dec;140(12):2531-2535.e2. doi: 10.1016/j.jid.2020.04.013. Epub 2020 May 16.

Authors

Emma Guttman-Yassky¹, Richard L Gallo², Ana B Pavel¹, Teruaki Nakatsuji², Randall Li¹, Ning Zhang¹, Elizabeth Messersmith³, Tomoko Maeda-Chubachi⁴

Affiliations

¹ Department of Dermatology, Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA.
² Department of Dermatology, UC San Diego School of Medicine, San Diego, California, USA.
³ Novan, Inc, Morrisville, North Carolina, USA.
⁴ Novan, Inc, Morrisville, North Carolina, USA. Electronic address: tmaeda-chubachi@novan.com.

PMID: 32428543
DOI: 10.1016/j.jid.2020.04.013

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Anti-Infective Agents / administration & dosage*
Anti-Infective Agents / metabolism
Anti-Inflammatory Agents / administration & dosage*
Anti-Inflammatory Agents / metabolism
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / genetics
Dermatitis, Atopic / immunology
Dermatitis, Atopic / microbiology
Disease Models, Animal
Drugs, Investigational / administration & dosage
Drugs, Investigational / metabolism
Humans
Mice
Mice, Transgenic
Nitric Oxide / metabolism
Ovalbumin / administration & dosage
Ovalbumin / immunology
Receptor, Fibroblast Growth Factor, Type 1 / genetics
Siloxanes / administration & dosage*
Siloxanes / metabolism
Skin Cream / administration & dosage
Skin Cream / metabolism
Staphylococcal Skin Infections / drug therapy*
Staphylococcal Skin Infections / genetics
Staphylococcal Skin Infections / immunology
Staphylococcal Skin Infections / microbiology
Staphylococcus aureus / drug effects
Staphylococcus aureus / isolation & purification

Substances

Anti-Infective Agents
Anti-Inflammatory Agents
Drugs, Investigational
Siloxanes
Nitric Oxide
Ovalbumin
Fgfr1 protein, mouse
Receptor, Fibroblast Growth Factor, Type 1
berdazimer sodium

Associated data

ClinicalTrials.gov/NCT03431610